Australia markets closed

Allogene Therapeutics, Inc. (ALLO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.80+0.48 (+4.65%)
At close: 04:00PM EDT
11.34 +0.54 (+5.00%)
After hours: 05:51PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.48B
Enterprise value 1.09B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)5.86k
Price/book (mrq)1.85
Enterprise value/revenue 4.42k
Enterprise value/EBITDA -3.71

Trading information

Stock price history

Beta (5Y monthly) 0.52
52-week change 3-55.50%
S&P500 52-week change 3-16.62%
52-week high 325.00
52-week low 36.43
50-day moving average 313.95
200-day moving average 311.25

Share statistics

Avg vol (3-month) 31.71M
Avg vol (10-day) 32.41M
Shares outstanding 5143.81M
Implied shares outstanding 6N/A
Float 882M
% held by insiders 129.87%
% held by institutions 172.53%
Shares short (14 Sept 2022) 422.22M
Short ratio (14 Sept 2022) 417.13
Short % of float (14 Sept 2022) 424.74%
Short % of shares outstanding (14 Sept 2022) 415.45%
Shares short (prior month 14 Aug 2022) 422.57M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 June 2022


Profit margin 0.00%
Operating margin (ttm)-124,756.27%

Management effectiveness

Return on assets (ttm)-18.57%
Return on equity (ttm)-33.71%

Income statement

Revenue (ttm)247k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)95.50%
Gross profit (ttm)-181.69M
EBITDA -294.21M
Net income avi to common (ttm)-307.69M
Diluted EPS (ttm)-2.20
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)490.49M
Total cash per share (mrq)3.41
Total debt (mrq)103.58M
Total debt/equity (mrq)12.91
Current ratio (mrq)11.42
Book value per share (mrq)5.58

Cash flow statement

Operating cash flow (ttm)-205.08M
Levered free cash flow (ttm)-109.27M